Tolsura (Itraconazole) Patent Expiration, LOE Window & CMS Spending

Tolsura (Itraconazole) by Mayne International Pty: FDA Orange Book LOE 2033-06-21, 7 AB generics, $1.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne International Pty
FDA Application & PathwayN208901 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-06-21
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$559K
2024 Medicaid Spend$512K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel